Literature DB >> 27208592

C-reactive protein, obesity, and the risk of arterial and venous thrombosis.

L D Horvei1,2,3, G Grimnes1,2,3, K Hindberg1,2, E B Mathiesen1,4, I Njølstad1,5, T Wilsgaard5, J Brox1,6, S K Braekkan1,2,3, J-B Hansen1,2,3.   

Abstract

UNLABELLED: Essentials We performed repeated measurements of C-reactive protein (CRP) and obesity in a cohort study. CRP was associated with risk of myocardial infarction and venous thromboembolism. CRP was a mediator for risk of myocardial infarction in obese men and women. CRP was a partial mediator for risk of venous thromboembolism in obese women, but not in men.
SUMMARY: Background Low-grade inflammation in obesity may be a shared pathway for the risk of venous thromboembolism (VTE) and myocardial infarction (MI). Objectives To investigate the associations between repeated measurements of C-reactive protein (CRP) and the risks of MI and VTE, and to explore whether CRP mediated these risks in obese subjects. Methods CRP and obesity measures were collected from 15 134 subjects who participated in one or more surveys of the Tromsø study in 1994-1995, 2001-2002, or 2007-2008. Incident VTEs and MIs were registered until 1 January 2011. Time-varying Cox regression models were used to calculate hazard ratios of MI and VTE according to categories of CRP and obesity measures. Results There were 291 VTEs and 920 MIs during follow-up. High levels of CRP (≥ 3 mg L(-1) versus < 1 mg L(-1) ) were associated with increased risks of MI (hazard ratio [HR] 1.73; 95% confidence interval [CI] 1.32-2.26) and VTE (HR 1.84; 95% CI 1.22-2.78) in women, but only with MI in men (HR 1.93; 95% CI 1.53-2.44). All obesity measures showed stronger associations with CRP in women than in men. In obese women (body mass index [BMI] of ≥ 30 kg m(-2) versus < 25 kg m(-2) ), adjustment for CRP attenuated the risk estimate for VTE by 22%, whereas the incidence rates of VTE increased with combined categories of higher BMI and CRP. No association was found in men. Conclusions Our findings suggest that low-grade inflammation, assessed by measurement of CRP, is associated with the risks of MI and VTE, and may be a shared pathway for MI and VTE in obesity.
© 2016 International Society on Thrombosis and Haemostasis.

Entities:  

Keywords:  cardiovascular diseases; inflammation; obesity; risk factors; venous thrombosis

Mesh:

Substances:

Year:  2016        PMID: 27208592     DOI: 10.1111/jth.13369

Source DB:  PubMed          Journal:  J Thromb Haemost        ISSN: 1538-7836            Impact factor:   5.824


  24 in total

1.  Letter to the Editor: "Risk of venous thromboembolism among patients with vasculitis: a systematic review and meta-analysis".

Authors:  Andreas Kronbichler; Jae Il Shin
Journal:  Clin Rheumatol       Date:  2016-09-22       Impact factor: 2.980

Review 2.  COVID-19 Infection and Circulating Microparticles-Reviewing Evidence as Microthrombogenic Risk Factor for Cerebral Small Vessel Disease.

Authors:  Che Mohd Nasril Che Mohd Nassir; Sabarisah Hashim; Kah Keng Wong; Sanihah Abdul Halim; Nur Suhaila Idris; Nanthini Jayabalan; Dazhi Guo; Muzaimi Mustapha
Journal:  Mol Neurobiol       Date:  2021-06-26       Impact factor: 5.590

3.  Hemostatic factors, inflammatory markers, and risk of incident venous thromboembolism: The Multi-Ethnic Study of Atherosclerosis.

Authors:  Line H Evensen; Aaron R Folsom; James S Pankow; John-Bjarne Hansen; Matthew A Allison; Mary Cushman; Pamela L Lutsey
Journal:  J Thromb Haemost       Date:  2021-05-07       Impact factor: 16.036

4.  Weight Change and Risk of Venous Thromboembolism: The Tromsø Study.

Authors:  Lars Daae Horvei; Sigrid K Brækkan; John-Bjarne Hansen
Journal:  PLoS One       Date:  2016-12-20       Impact factor: 3.240

5.  Serum C-reactive protein increases the risk of venous thromboembolism: a prospective study and meta-analysis of published prospective evidence.

Authors:  Setor K Kunutsor; Samuel Seidu; Ashley W Blom; Kamlesh Khunti; Jari A Laukkanen
Journal:  Eur J Epidemiol       Date:  2017-07-17       Impact factor: 8.082

6.  Acute cerebrovascular disease following COVID-19: a single center, retrospective, observational study.

Authors:  Yanan Li; Man Li; Mengdie Wang; Yifan Zhou; Jiang Chang; Ying Xian; David Wang; Ling Mao; Huijuan Jin; Bo Hu
Journal:  Stroke Vasc Neurol       Date:  2020-07-02

Review 7.  Inflammatory Biomarkers in the Short-Term Prognosis of Venous Thromboembolism: A Narrative Review.

Authors:  Francisco Galeano-Valle; Lucía Ordieres-Ortega; Crhistian Mario Oblitas; Jorge Del-Toro-Cervera; Luis Alvarez-Sala-Walther; Pablo Demelo-Rodríguez
Journal:  Int J Mol Sci       Date:  2021-03-05       Impact factor: 5.923

8.  Evaluation of Deep Vein Thrombosis Risk Factors After Arthroscopic Posterior Cruciate Ligament Reconstruction: A Retrospective Observational Study.

Authors:  Pu Ying; Wenge Ding; Xiaowei Jiang; Yue Xu; Yi Xue; Qiang Wang; Lei Zhu; Xiaoyu Dai
Journal:  Clin Appl Thromb Hemost       Date:  2021 Jan-Dec       Impact factor: 2.389

9.  Circulating Total Bilirubin and Future Risk of Hypertension in the General Population: The Prevention of Renal and Vascular End-Stage Disease (PREVEND) Prospective Study and a Mendelian Randomization Approach.

Authors:  Setor K Kunutsor; Lyanne M Kieneker; Stephen Burgess; Stephan J L Bakker; Robin P F Dullaart
Journal:  J Am Heart Assoc       Date:  2017-11-13       Impact factor: 5.501

10.  Risk factors for recurrence in deep vein thrombosis patients following a tailored anticoagulant treatment incorporating residual vein obstruction.

Authors:  Michael Nagler; Hugo Ten Cate; Martin H Prins; Arina J Ten Cate-Hoek
Journal:  Res Pract Thromb Haemost       Date:  2018-02-03
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.